A Comparison of the Evolution, Structure, and Function of SARS-CoV and SARS-CoV-2 Spike Proteins by Michaels, Tai
The Yale Undergraduate Research Journal 
Volume 1 
Issue 1 Fall 2020 Article 25 
2020 
A Comparison of the Evolution, Structure, and Function of SARS-
CoV and SARS-CoV-2 Spike Proteins 
Tai Michaels 
Yale University 
Follow this and additional works at: https://elischolar.library.yale.edu/yurj 
 Part of the Biology Commons, Cell and Developmental Biology Commons, Diseases Commons, and 
the Immunology and Infectious Disease Commons 
Recommended Citation 
Michaels, Tai (2020) "A Comparison of the Evolution, Structure, and Function of SARS-CoV and SARS-
CoV-2 Spike Proteins," The Yale Undergraduate Research Journal: Vol. 1 : Iss. 1 , Article 25. 
Available at: https://elischolar.library.yale.edu/yurj/vol1/iss1/25 
This Article is brought to you for free and open access by EliScholar – A Digital Platform for Scholarly Publishing at 
Yale. It has been accepted for inclusion in The Yale Undergraduate Research Journal by an authorized editor of 
EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact 
elischolar@yale.edu. 
A Comparison of the Evolution, Structure, and Function of SARS-CoV and SARS-
CoV-2 Spike Proteins 
Cover Page Footnote 
Thank you to Amelia Hallworth, Will Oles, Dr. Iain Dawson, and the YURJ team for their feedback and 
guidance. 
This article is available in The Yale Undergraduate Research Journal: https://elischolar.library.yale.edu/yurj/vol1/iss1/
25 
   
        YURJ | yurj.yale.edu                     
Social Sciences 
   1  
 
      TEM | Stru tural Biology           VOL. 1.1 | Nov. 2020 
 
 
      
     Tai Michaels1 
     1Yale University 
 










The recent COVID-19 pandemic has exploded across 
the globe and slowed much of the world to a standstill as it 
forced the largest quarantines in history1. Although other 
coronaviruses (CoVs) are present in human and other mammal 
populations2, the causative coronavirus pathogen, named 
SARS-CoV-23, is now the third novel coronavirus (nCoV) to 
attain epidemic proportions within the past two decades along 
with SARS-CoV (2002) and MERS-CoV (2012)4. Similar to 
past outbreaks, COVID-19 has been characterized by 
respiratory complications and has limited treatment options with 
vaccines still under development5,6. 
Unlike prior nCoV’s, however, SARS-CoV-2 has 
infected multiple orders of magnitude more people and has a 
much lower case fatality rate. As of July 27, 2020, COVID-19 
has caused over 16 million confirmed cases globally with over 
600 thousand confirmed deaths7 potentially due to a higher 
reproductive number (which is contested)8,9 or a higher 
asymptomatic case proportion10,11. However, most research 
findings point towards a case fatality rate of 1-2%12 which 
indicates that reported cases may be as little as 20% of the true 
number of infections13,14. This stands in stark contrast to SARS-
CoV which had 8,500+ cases and a 6-10% case fatality rate15. 
SARS-CoV-2 evidently has a vastly different epidemiological 
character for unclear reasons, and understanding why could be 
critical for targeting response efforts and preparing for the future 
pandemics of the modern age. As the scientific community 
scrambles to understand this virus, it is important to recognize 
both its similarities with past outbreaks and what makes 
COVID-19 fundamentally different.  
One crucial, conserved component of all CoV’s is the 
spike (S) protein - a structural protein of the viral capsid. The S 
protein is a portion of the viral capsid which binds the host cell 
receptor and initiates the introduction of the viral contents into 
the cell. Within the S protein, one of the most important portions 
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Abstract 
As the COVID-19 pandemic has developed into the largest pandemic of the twenty-first century, it has become apparent that this 
disease, caused by the SARS-CoV-2 virus, is unlike anything the modern world has faced before. Not only has the disease infected 
more than 16 million people worldwide, but its rapid spread has drawn global attention to the gaps in our understanding of its 
pathogenesis and the development of vaccines and treatments. One of the most important topics of research in the disease is the 
viral spike (S) protein which facilitates binding and entering host cells and plays a key role in host specificity and pathogenicity 
among others. This review attempts to capture the importance of S protein in this new disease through evolutionary, structural, and 
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is the receptor binding domain (RBD) which is the portion of 
the protein which initiates binding with the cell receptor16. In 
both SARS-CoV and SARS-CoV2, the RBD primarily binds 
angiotensin converting enzyme 2 (ACE2)17,18. In this literature 
review, I aim to capture the scope of what is known of the 
evolution and function of the RBD in CoV’s with specific focus 





Coronaviruses are members of the family 
coronaviridae which is composed of enveloped +ssRNA viruses 
which infect mammals and birds and includes genuses 
alphacoronavirus, betacoronavirus, gammacoronavirus, and 
deltacoronavirus which are generally delineated by sequence 
homology19. Genus alphacoronavirus includes diverse bat 
coronaviruses as well as two notable human coronaviruses 
(HCoVs), HCoV-NL63 and HCoV-229E, which both cause 
relatively mild influenza-like symptoms in infected individuals. 
Genus betacoronavirus, which includes the three recent nCoVs 
and is the most thoroughly studied genus, has been subdivided 
into 4 subgenus lineages. Genuses gammacoronavirus and 
deltacoronavirus are not currently known to contain HCoVs and 
are primarily composed of avian coronaviruses20. The most 
recent common ancestor (MRCA) of coronaviruses was 10ka 
(kiloannum), and the MRCAs of the four genuses were between 
4-5ka21.  
The four subgenuses of betacoronavirus have been 
termed embecoronavirus (subgroup A), sarbecoronavirus 
(subgroup B), merbecoronavirus (subgroup C), and 
nobecoronavirus (subgroup D). Embecoronavirus contains 
several bat CoVs along with HCoV-OC43 which (similar to 
HCoV-NL63 and HCoV-229E) causes mild influenza-like 
symptoms. Sarbecoronavirus includes the severe acute 
respiratory syndrome coronavirus (SARS-CoV), the more 
recent SARS-CoV-2 (causal agent of COVID-19), and a range 
of primarily bat CoVs termed severe acute respiratory syndrome 
related coronaviruses (SARSr-CoV). Merbecoronavirus 
contains the middle east respiratory syndrome coronavirus 
(MERS-CoV) along with related (primarily bat) coronaviruses. 
MERS-CoV has been excluded from the study due to its much 
lower genetic relatedness and distinct epidemiologic character4. 
Although it merits further study in light of ongoing cases and 
much higher case fatality rates4, it is beyond the scope of this 
review. Nobecoronavirus is a lineage of mostly bat 
coronaviruses with no known HCoVs19–21.  
Of these lineages, the one of most interest to the study 
is subgenus sarbecoronavirus since it contains SARS-CoV-2 
(the causal agent of COVID-19) along with SARS-CoV, a 
relatively closely related nCoV22. Genetically, have genomes of 
27.9kb and 29.9kb respectively13, both trace their origins to bat 
CoVs2, and share primarily droplet and fomite23 transmission 
(although aerosol transmission is debated24,25). The RBDs of 
SARS-CoV and SARS-CoV-2 are very distinct compared to 
other sarbecoronaviruses26 but bear strong resemblance to one 
another19. The overall genetic similarity of SARS-CoV-2 to 
SARS-CoV is 79.5%19 (with its most closely related identified 
relative at 96.2%27). Both viruses have generally similar S 
protein structures19 and retain the asymmetric homotrimer with 
two RBDs “down” and one “up”28. However, their most recent 
common ancestor (MRCA) has been estimated to have occured 
1,400 years ago27, and their accumulated differences have 
clearly made them very different epidemiologically. 
 
2.2 Lifecycle 
CoVs generally follow a pattern of evolution and 
diversification in reservoir organisms - typically birds for 
gammacoronavirus and deltacoronavirus, and bats for 
alphacoronavirus and betacoronavirus. Rarely, CoV strains spill 
over into other mammal populations through contact with bats 
2
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or birds21. HCoVs tend to result from secondary transmission of 
viral strains from intermediate mammal hosts. For example, 
MERS-CoV and HCoV-229E are believed to have originated 
from bats with an intermediate host of dromedary camels 
(Camelus dromedarius)29. Many other HCoVs have been 
demonstrated to have been transmitted to humans from bats 
through various mammalian intermediate hosts although not all 
have been studied20.  
In the case of SARS-CoV, the virus most likely 
originated in bats and then was transmitted to palm civets 
(Paradoxurus hermaphroditus) and raccoon dogs (Nyctereutes 
procyonoides) which then transmitted the virus to humans20. 
The most closely related strain (WIV16) has 96% genetic 
similarity and 97% amino acid similarity in the S protein and 
was isolated from horseshoe bats further supporting the bat 
origin theory30. Broader study found a diverse group of SARSr-
CoVs in these and other bats from which SARS-CoV and 
SARS-CoV-2 are believed to be descendents2. 
The origin of SARS-CoV-2 is still up to some debate. 
The most closely related CoV isolated so far is RaTG13 isolated 
from horseshoe bats in 2013 with 96.2% genetic similarity19,31, 
but since early cases had no clear exposure to bats, the existence 
of an unknown intermediate host is likely2,19. One study of a 
related pangolin CoV found “conclusive” evidence that the 
virus was transmitted from bats to a pangolin reservoir 
population from which RaTG13 and SARS-CoV-2 are 
descended32. However, other studies noted the pangolin CoV is 
likely an outgroup rather than a direct ancestor of SARS-CoV-
2 and that the pangolin CoV and SARS-CoV likely both 
diverged from a horseshoe bat CoV2,27. The most closely related 
bat coronaviruses sequenced were three times more closely 
related for SARS-CoV than for SARS-CoV-22, so with further 
sequencing of related SARSr-CoVs in bats and other organisms, 
a clearer picture may emerge in the coming. The most closely 
related bat coronaviruses sequenced were three times more 
closely related for SARS-CoV than for SARS-CoV-22, so with 
further sequencing of related SARSr-CoVs in bats and other 
organisms, a clearer picture may emerge in the future2. 
 
2.3 Evolution of the S Protein 
More specific to the role of the S protein in evolution, 
it is believed that the ability of the S protein to bind ACE2 
originates from the ability to bind ACE2 orthologs in bat 
species, but it is not a conserved trait in the common ancestors 
of SARS-CoV and SARS-CoV-218. One other HCoV (HCoV-
NL63) associated with more mild respiratory disease also binds 
ACE2 in humans19, but is not closely related at all to SARSr-
CoVs since it is in the alphacoronavirus genus33 and has a 
distinct binding interaction34. In general, the S protein is highly 
mutable35 and a large degree of the RBD similarities between 
SARS-CoV and SARS-CoV-2 are likely a product of 
convergent evolution. 
In terms of proximal evolution, related viruses 
identified in pangolin populations share several key similarities 
to SARS-CoV-2 in the RBD (while RaTG13 does not), but do 
not possess a key furin cleavage site (discussed later) which may 
have derived from evolution in human populations from 
repeated introductions as in MERS36. Further evolution of the 
spike protein post transition to human hosts is evidenced by the 
increasing predominance of the G614 mutant form of the spike 
protein which has been correlated with higher case-fatality rates, 
viral loads, and potentially transmissibility37,38. 
 
3. STRUCTURE 
CoV genomes all contain variants of four key structural 
proteins - nucleocapsid (N), matrix (M), envelope (E), and spike 
(S) proteins - in addition to highly variable numbers of non-
structural proteins (nsp) often in overlapping open reading 
frames (ORFs)39. In SARS-CoV and SARS-CoV-2, the genome 
has two majors ORFs (ORF1a and ORF1b) which contain 15 
nsp. The final third of the genome contains four structural 
3
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proteins13,22,40 which are separated by accessory proteins which 
are not believed to be essential to viral function41. The gene 
encoding the S protein is located after ORF1ab and 
nonstructural protein 2 (ns2)40 and is about 3800nt13 and 1270 
amino acids22. 
 
3.1 Spike Protein 
Structurally, the S protein is expressed as a homotrimer 
spike on the viral surface with each monomer noncovalently 
linked42. This trimer form has also been described in related 
CoVs43. Each S protein monomer is made up of three domains. 
The extracellular domain (EC), the transmembrane anchor 
domain, and a small intracellular tail domain. Of these, the EC 
is of greatest interest due to its role in host cell binding and as a 
potential antibody target. The EC contains two domains: the S1 
domain which is primarily involved with host cell binding and 
the S2 domain which is primarily involved in fusion with the 
host cell44,45. 
The S1 domain has been described as having four 
subdomains: the N-terminal domain (NTD) and three C-
terminal domains numbered CTD1, CTD2, and CTD3. Of these, 
CTD1 (the closest to the NTD) is of greatest interest to this 
review since it contains the RBD42. CTD2 consists primarily of 
beta sheets extending out from CTD3 which is bound to S246. 
As compared to the general genetic stability of coronaviruses 
and overarching similarities of major S protein structures, the 
RBD is one of the most mutable regions of the virus39. For 
example, just three point mutations were found to be key to the 
transition of SARS-CoV to humans, and the RBD had very little 
similarity to other sarbecoronaviruses26,35. 
Studies using cryo-EM have identified four distinct 
conformations of the trimer. One of these is a symmetric form 
of the trimer which is unable to bind to ACE2 and thus unable 
to fuse the host cell. The CTD1 domains in this conformation 
are said to be in a “down” state and are folded in towards the 
rest of the spike protein which blocks the RBD from being able 
to interact with ACE242,46. The other three each have one of the 
RBD’s in an “up” conformation in which the CTD1 inverts 
exposing the RBD allowing binding28,42. Each of these three 
“active” conformations binds ACE2 at a different angle to the S 
protein46. Another study identified only two binding 
conformations47, and the resolution of binding states so far 
described is in the range of 5-10Å, so further research is likely 
necessary. 
The S2 subunit is a class I viral fusion protein which 
facilitates fusion and viral entry to the cell16,39. The protein 
contains two heptad repeats (HR1 and HR2) which integrate 
into the membrane and facilitate endosome formation42. 
 
3.2 Host Receptor 
ACE2, the RBD’s binding target, is a homodimer with 
three domains. Each monomer has a single pass transmembrane 
domain, a collectrin-like domain (CLD) just outside the cell 
membrane, and a peptidase domain (PD) which extends further 
into the extracellular space. The RBD binds ACE2 on one limb 
of the binding pocket near the N-terminal domain17. It primarily 
interacts with one of the PDs alpha helices α1 and α2 as well as 
beta sheets β3 and β448.  
One trait of SARS-CoV that has not yet been 
conclusively demonstrated in SARS-CoV-2 is the ability to 
utilize CD209L (also called DC-SIGN) as a host cell receptor 
instead of ACE249. CD209L is a C-type lectin receptor present 
in many immune cells as well as alveolar cells and is targeted 
by other viruses including HIV, hepatitis C, ebola, and HCoV-
229E49,50. One study has made a model of potential SARS-CoV-
2 CD209L binding with a heavily glycosylated NTD, but it has 
yet to be shown experimentally50. While it is widely recognized 
that ACE2 is the primary receptor for both viruses, CD209L 
deserves further consideration in the face of the many unknowns 
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3.3 Receptor Binding Domain 
The RBD’s primary role is binding the host cell through 
the receptor angiotensin converting enzyme 2 (ACE2)16,17. The 
RBD has a core complex of about 170 amino acids forming 
disulfide linked beta sheets which forms a projection from the 
rest of S126. Within the RBD is a section called the receptor 
binding motif (RBM) of about 70 residues. The RBM is the only 
part of the S protein which directly interacts with ACE2 and is 
thus critical to binding and host specificity26. The RBM forms a 
concave structure of two antiparallel beta sheets linked on one 
end by a loop and on the other by strands connecting to the RBD 
core complex26,42,46. 
Despite macro-scale similarities, there are many key 
differences in the region of the S protein. According to one 
study, the genetic sequence of SARS-CoV-2 only indicates 6 
amino acid substitutions in the RBD - P348A, E354N, V417K, 
K430N, T438S, N519H - out of 17 substitutions in S1 and 27 in 
all of S (out of 1273 residues)22. Also worth noting are 
significant changes in many accessory proteins including 3ab 
and 8a, but these are not the focus of this review22. 
Another study comparing an X-ray crystallography 
structure of SARS-CoV S45 and a cryo-EM structure of SARS-
CoV-2 S, the overall similarity was strong in the RBD with only 
a 0.64Å root mean square deviation in the core sequence of 120 
alpha carbons46. In terms of the specific residues interacting 
with ACE2, however, there were many notable changes. Three 
substitutions in the region interacting with the α1 N-terminal 
region and one substitution towards the C-terminal end were 
noted. The middle portion contained five substitutions including 
a key V404 → K417 substitution that may increase binding affinity 
to D30 on α1 by forming a new salt bridge. Another notable 
substitution is R426 → N439 weakening a salt bridge to D329 on a 
helix near ꞵ4. The study also notes, however, that overall change 
in binding affinity could not be determined from the structure 
alone46. One study has found similar ACE2 binding affinities 
for the two viruses48 while others have found that SARS-CoV-
2 S protein has as much as 10 times greater affinity47,61. 
It is worth noting that the comparison of genetic 
sequences yielding 6 substitutions in the RBD surveyed a wide 
range of SARS-CoV and SARS-CoV-2 sequences to ensure that 
these were polymorphisms representative of true differences 
between the populations22. The structural comparison which 
noted 10 substitutions compared a single representative 
structure of each virus, thus the difference in approach may 
account for some of the differences in results of these and other 
analyses. 
 
3.4 Proteolytic Activation 
After binding ACE2, another critical function of the S 
protein is proteolytic activation. Cleavage at one or more sites 
in the S protein are necessary to activate S2 activity and initiate 
endosome fusion34,42,51,52. The primary cleavage region is 
between the S1 and S2 subunits allowing them to separate and 
S2 to activate, but there is increasing evidence for an additional 
cleavage site within S2. This site, called the S2’ cleavage site, 
is located between the L segment of S2 and the heptad repeats 
and is believed to be similarly crucial to viral function34,51. 
Unlike related viruses such as MERS-CoV, the S protein is not 
cleaved during development and is instead cleaved by host cell 
proteases upon binding53. Additionally, unlike some viruses 
including influenza, the S1 and S2 domains are not linked by 
disulfide bonds and are therefore bound only by noncovalent 
bonds after S1/S2 cleavage34. While some studies on related 
strains of murine CoV have found that proteolytic cleavage is 
not necessary for viral fusion54,55, it increases the rate of fusion 
by 2-3 orders of magnitude55. 
A variety of enzymes have diverse involvements with 
the proteolytic activation of the S protein. The primary enzyme 
involved in S protein cleavage is a type II transmembrane serine 
protease (TTSP) called transmembrane protease serine 2 
(TMPRSS2) which cleaves the protein in multiple places 
5
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including between S1 and S245 and at S2’51 leading to activation 
of S2 fusion activity52,56–58. TMPRSS2 is notably present in 
similar cell types to ACE2 including alveolar cells which 
SARS-CoV and SARS-CoV-2 notably infect56,58. This protease 
activity also produces fragments of the S protein which may 
bind antibodies helping evade humoral immunity34,56. A 
different type of serine protease, elastase, has been found to 
cleave only the S2’ cleavage region, but it may be important in 
some severe cases since elastase is released by neutrophils in 
response to many infections. This would appear to indicate that 
the body’s inflammatory response increases the proteolytic 
activation of the S protein55,59. 
Another enzyme known to cleave the S protein is 
cathepsin L, a lysosomal peptidase, which cleaves the protein 
between the S1 and S2 subunits thereby activating fusion 
activities60,61. However, unlike TMPRSS2, cathepsin L is an 
intracellular protein and can only affect S protein activity after 
endocytosis has begun56,57. Though it is sufficient for fusion61, 
TMPRSS2 alone is more efficient than cathepsin L62. Another 
TTSP, human airway trypsin-like protease (HAT), is also able 
to cleave between S1 and S2 in both a cis and trans state. 
However, HAT cannot induce fusion activity in the absence of 
cathepsin L52. There are still significant gaps in our 
understanding of how the necessity of cleavage at the cell 
surface, in late endosomes, or lack thereof affects viral and 
epidemiologic characteristics. 
Proteolytic cleavage is also one of the significant 
differences in the S protein between SARS-CoV-2 and SARS-
CoV. While MERS-CoV and some other HCoVs such as 
HCoV-OC43 and HCoV-HKU1 have one or more furin 
cleavage sites, SARS-CoV has no significant furin protease 
activity34, and furin cleavage sites in the S protein have not been 
identified in any of closely related SARSr-CoVs such as 
RaTG13 and the pangolin CoVs36. However, recent studies have 
predicted a furin cleavage site along with some associated O-
linked glycans in SARS-CoV-2 in the S1/S2 cleavage 
region44,47. Comparison of fusion activity in the presence of 
TMPRSS2 and cathepsin L inhibitors found that SARS-CoV-2 
maintained a low but significantly higher rate of fusion than 
SARS-CoV which was interpreted as a result of additional furin 
proteolytic activation62 It has been shown in a porcine CoV that 
a single point mutation creating a furin cleavage site rendered 
trypsin proteases unnecessary for fusion63, and thus, the furin 
cleavage site may serve to increase the ability of SARS-CoV-2 
to fuse with host cell membranes. Crucially, furin is expressed 
in far more cell types than TMPRSS2 and may thus contribute 
to the virus’ capability to infect a wide range of cells including 




It is still unclear how mutations in the SARS-CoV-2 
RBD have affected its binding affinity for ACE2, but the general 
consensus is that SARS-CoV-2 has a greater binding affinity 
which may play a role in its pathology. Studies in related viruses 
have found that the patterns of S protein binding are correlated 
with pathogenicity65 indicating that the changes in binding 
interaction observed between the viruses could be key to 
epidemiologic properties. A study of HCoV-NL63 has also 
suggested that lower observed binding affinity for ACE2 
compared to SARS-CoV may have contributed to lower 
pathogenicity33.  
While there is both evidence for enhanced binding 
affinity and for the role of binding affinity in pathogenicity, the 
extent to which this may explain the dramatic epidemiological 
differences between the viruses is unclear. It is likely that the 
altered RBD increases infectivity and enhances transmission66, 
but elucidating the magnitude of the effect from the wide range 
of factors has and will likely continue to prove extremely 
challenging. 
6
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Differential cleavage certainly is a significant 
difference between the viruses, but conclusive evidence for any 
epidemiological significance is still lacking. It has been 
predicted that the addition of a furin cleavage site in the SARS-
CoV-2 genome will enable the virus to infect a greater range of 
human cell types due to the more widespread presence of furins 
and therefore increase the ease of transmission44. However, 
studies have shown that both viruses infect the same cell types 
when tested in vitro suggesting that this effect may not be 
present62. Furthermore, in a single-cell RNA-seq study of a wide 
range of cell types, ACE2 (not TMPRSS2 or other proteolytic 
activators) was found to be the limiting factor on capacity for 
viral infection64. 
On a final note, the importance of S protein to host 
transitions and treatments make it an important determinant of 
the likelihood of future nCoV outbreaks. In the case of SARS-
CoV, the transition from palm 
civet to human hosts required only 
two amino acid substitutions in the 
RBD domain to yield a virus 
capable of infecting humans and 
with 3-4x the binding affinity it 
had in civets35. For SARS-CoV-2, 
just six substitutions in the RBD 
separate it from SARS-CoV, but it 
has already proved to be a much 
more devastating epidemic22,67, 
and the more recent G614 mutation may have further increase 
its pathogenicity and transmissibility37,38. Given the relatively 
high mutability of this protein39, it seems that further zoonosis 




Since there are still no approved vaccines or treatments 
for SARS-CoV-2, it is crucial to understand the ways in which 
S1 and its interactions may be exploited for treatments to 
prevent viral binding and fusion. The S protein is widely 
regarded as an important target for antibody, protease inhibitor, 
and vaccine development62,68. 
Much of the ongoing research on treatments for SARS-
CoV focuses on developing antibody therapies. One of the most 
promising targets for monoclonal antibodies is the S protein 
which has seen significant research, but these therapies are 
susceptible to small mutations in the crucial RBD yielding 
resistance26,28. On the other hand, multiple studies have 
demonstrated antibody cross neutralization of SARS-CoV and 
SARS-CoV-2 indicating that there may be some conserved 
regions47,62,68.  
Some studies have examined the effects of TMPRSS2 
inhibitors due to the importance of it and other trypsin-like 
proteases to viral fusion. One study found strong fusion 
inhibition by using camostat 
mesylate (although the SARS-
CoV-2 notably had more residual 
activity than SARS-CoV 
indicating residual fusion 
activity)62. Also notable is that 
studies in TMPRSS2 -/- mutant 
mice have found no increased 
fatality or other significant 
changes in phenotype implying 
that TMPRSS2 inhibitors may be 
safely used although confirmation for humans has yet to occur69. 
Other studies have confirmed that inhibitors of cathepsin L 
reduce SARS-CoV-2 fusion61,62, but not nearly as much as 
TMPRSS2 inhibitors and thus are of less therapeutic 
importance62. Inhibitors of furins exist, but furins are widely 
expressed and play many critical functions in the body. 
However, it may be important to note that while proteases 
dramatically increase the rate of viral fusion, they are not strictly 
necessary for it54,55, and while studies of protease inhibitors 
 
“Given the relatively high 
mutability of this protein, it 
seems that further zoonosis or 
recurrence of past nCoVs 
seem likely within the 
foreseeable future. 
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have demonstrated efficacy in vitro, the effects of these are 
unknown in human systems as of yet58. 
Additionally, most current front-line treatments are 
more general, focusing on dampening the cytokine storm such 
as tocilizumab or acting as broad spectrum antivirals such as the 
nucleoside analog remdesivir. These treatments have proven 
useful, but it is quite possible that specific treatments such as S-
protein targeted antibodies could prove more effective with less 
nontarget effects than broad spectrum treatments. Targeted 
treatments also have the ability to be administered along with 
broad spectrum or other targeted therapeutics since they can act 
constructively to achieve more complete effectiveness. 
 
4.3 Vaccines 
Thus far, many of the vaccine candidates for SARS-
CoV with the most promise are whole virus or S protein 
isolates68. These are also the most common targets for SARS-
CoV-2 vaccines by number of vaccines under investigation, and 
even the frontrunner nucleic acid vaccines primarily target 
mRNA and DNA sequences which encode the S protein6.  
Furthermore, there is strong evidence for conserved 
regions from high degrees of cross reactivity of antibodies 
between SARS-CoV and SARS-CoV-248,60,62 but not other 
related CoVs62. Since 70% of SARS-CoV antibodies target 
structural proteins including the prominent S protein62, it seems 
probable that changes in SARS-CoV-2 S have not directly 
yielded immune evasion (although indirect evasion including 
additional cleavage is under investigation32,54). Therefore, it 
may be possible to create vaccines that induce vigorous immune 
responses to conserved regions of the S protein to confer lasting 
immunity against COVID-19 and future related pandemics. 
However, it is also worth noting that the S1 domain, 
while a valuable target for treatments and vaccines, is also 
among the most mutable regions of the virus and thus may be 
more susceptible to the development of resistance39. Although 
clearly important, S protein is not the only factor in 
pathogenesis. Recent studies have implicated nsp2 and nsp3 as 
key to pathogenicity70 and potentially nsp1 in related CoVs71. 
Interestingly, currently identified broad spectrum antiviral 
treatments which have demonstrated efficacy in vitro including 
remdesivir and chloroquine are not believed to affect the S 
protein or its function72. 
 
5. DISCLAIMER 
COVID-19 research is a rapidly changing landscape, and while 
this review aims to be as up to date as possible at the time of its 
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